ArticleCurrent cancer therapy reviews2011
Angiogenin as a molecular target for the treatment of prostate cancer.
Article in Current cancer therapy reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Unveiling the Dichotomy of Urinary Proteins: Diagnostic Insights into Breast and Prostate Cancer and Their Roles.Proteomes · 2023Review
- Neomycin, but Not Neamine, Blocks Angiogenic Factor Induced Nitric Oxide Release through Inhibition of Akt Phosphorylation.International journal of molecular sciences · 2022Article
- tiRNAs: Insights into Their Biogenesis, Functions, and Future Applications in Livestock Research.Non-coding RNA · 2022Review
- Chemosensitization of prostate cancer stem cells in mice by angiogenin and plexin-B2 inhibitors.Communications biology · 2020Article
- The Anti-Inflammatory Effects of Angiogenin in an Endotoxin Induced Uveitis in Rats.International journal of molecular sciences · 2020Article
- A Pilot Study on the Whole Exome Sequencing of Prostate Cancer in the Indian Phenotype Reveals Distinct Polymorphisms.Frontiers in genetics · 2020Article
- A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases.Journal of biomedical science · 2018Review
- Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival.Journal of cancer research and clinical oncology · 2018Article
- Apoptotic and anti-angiogenic effects of Salvia triloba extract in prostate cancer cell lines.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Mechanism and Function of Angiogenin in Prostate Cancer.Zhongguo sheng wu hua xue yu fen zi sheng wu xue bao = Chinese journal of biochemistry and molecular biology · 2015Article
- Physical activity and its mechanistic effects on prostate cancer.Prostate cancer and prostatic diseases · 2015Review
- Carboxylated acyclonucleosides: synthesis and RNase A inhibition.Molecules (Basel, Switzerland) · 2015Article
- Downregulation of angiogenin inhibits the growth and induces apoptosis in human bladder cancer cells through regulating AKT/mTOR signaling pathway.Journal of molecular histology · 2015Article
- Transcription of angiogenin and ribonuclease 4 is regulated by RNA polymerase III elements and a CCCTC binding factor (CTCF)-dependent intragenic chromatin loop.The Journal of biological chemistry · 2014Article
- Angiogenin reduces immune inflammation via inhibition of TANK-binding kinase 1 expression in human corneal fibroblast cells.Mediators of inflammation · 2014Article
- Thirty years of intracrinology.Ochsner journal · 2014Review
- Follistatin as potential therapeutic target in prostate cancer.Targeted oncology · 2013Review
- The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple.Pathology oncology research : POR · 2013Article
- The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors.World journal of surgical oncology · 2013Article
- Emerging role of angiogenin in stress response and cell survival under adverse conditions.Journal of cellular physiology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Angiogenin (ANG), a 14 kDa angiogenic ribonuclease, is upregulated in human prostate cancers, especially in hormone refractory diseases, and is the highest upregulated gene in Akt-driven prostate intraepithelial neoplasia (PIN) in mice. ANG has been shown to undergo nuclear translocation in both prostate cancer cells and cancer-associated endothelial cells where it binds to the promoter region of ribosomal DNA (rDNA) and stimulates ribosomal RNA (rRNA) transcription. ANG thus plays an essential role in prostate cancer progression by stimulating both cancer cell proliferation and tumor angiogenesis. A variety of ANG antagonists, including its antisense oligonucleotide, siRNA, soluble binding proteins, monoclonal antibody, enzymatic inhibitors, and nuclear translocation blockers, have all been shown to inhibit prostate cancer in various animal models. Accumulating evidence indicates that ANG is a molecular target for prostate cancer drug development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.